JPRN-UMIN000034931
Completed
Phase 2
PhaseII study of Nivolumab monotherapy for patients with occupational cholangiocarcinoma - OPAL study
ational Cancer Center Hospital East0 sites6 target enrollmentStarted: February 1, 2019Last updated:
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- ational Cancer Center Hospital East
- Enrollment
- 6
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\)Has merger or past history of autoimmune diseases. (2\)Has duplicate cancer. (3\)Has metastatic lesions in the brain or meningeal membrane. (4\)Has serious complications (intestinal obstruction, interstitial lung disease, diabetes etc.) (5\)Has pleural or ascites, that require treatment. (6\)Has poor pain control. (7\)Has received antibody therapy or medication therapy in the past. (8\)Has remain strongly influenced by side effects due to pretreatment or surgery. (9\)Has history of serious heart disease or one with the findings. (10\)Has systemic infections that require treatment. (11\)Isn't pregnant or breast\-feeding. (12\)Judged to be in a state lacking consent ability due to merger of dementia.
Investigators
Similar Trials
Recruiting
Phase 4
Phase II study of adjvant Nivolumab monotherapy for esophageal cancer.Esophageal cancerD004938JPRN-jRCT1031220223Yagi Koichi99
Completed
Phase 2
A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Studypleural mesothelioma10027412NL-OMON41970Antoni van Leeuwenhoek Ziekenhuis33
Active, not recruiting
Not Applicable
ivolumab in patients with progressive malignant pleural mesothelioma: NivoMesA single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes StudyMedDRA version: 17.1Level: LLTClassification code 10027408Term: Mesothelioma malignant advancedSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003935-20-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
Recruiting
Phase 2
Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS MalignanciesNL-OMON48940Bristol-Myers Squibb6
Active, not recruiting
Phase 1
An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Patients with High Grade Primary CNS Malignancies.Primary central nervous system (CNS) malignancies.MedDRA version: 20.0Level: LLTClassification code 10006153Term: Brain tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-004441-82-NOBristol-Myers Squibb International Corporation166